[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462541":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":35,"centralContacts":40,"locations":46,"responsibleParty":62,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":30,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":30,"enrollmentInfo":77,"targetDuration":30,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":48,"whyStopped":30,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"MetroHealth Medical Center","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose","EXPERIMENTAL","600mg treatment group will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.",[13],"Drug: Gabapentin",{"label":15,"type":10,"description":16,"interventionNames":17},"Medium dose","1800 mg treatment groups will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Control","PLACEBO_COMPARATOR","The control group will receive 2 placebo capsules of inert cellulose by mouth 3 times per day for 90 days.",[23],"Drug: Placebo",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Gabapentin","Generic gabapentin",[9,15],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Placebo","Inert cellulose",[19],[36],{"name":37,"affiliation":38,"role":39},"Dr. Kimberly Anderson, PhD","Metrohealth Medical Center-Case Western Reserve University School of Medicine","PRINCIPAL_INVESTIGATOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":30,"email":45},"Mayson Moore","CONTACT","216-957-3518","mmoore12@metrohealth.org",[47],{"facility":5,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Cleveland","Ohio","44109","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-81.69541,41.4995,{"lat":58,"lon":57},[61],{"name":42,"role":43,"phone":44,"phoneExt":30,"email":45},{"type":39,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Kimberly Anderson, PhD","Director, Northeast Ohio Regional SCI Model System",[66],{"name":67,"class":68},"National Institute on Disability, Independent Living, and Rehabilitation Research","FED","100462541","phase-4-feasibility-of-early-gabapentin-as-an-intervention-for-neurorecovery-100462541",false,"NCT05302999","Feasibility of Early Gabapentin as an Intervention for Neurorecovery","Inclusion Criteria:\n\n1. Traumatic SCI;\n2. All levels of SCI;\n3. All severities of SCI, AIS A-D;\n4. Age 18 years and older.\n5. Agree to participate and start study drug within 120 hours' post-injury.\n6. Adequate cognition and communication to provide informed consent\n\nExclusion Criteria:\n\n1. Presence of moderate\u002Fsevere traumatic brain injury (TBI) as defined by Glasgow Coma Score (GCS) \\\u003C 13 at 120 hours' post-injury.\n2. Documented use of gabapentinoids at the time of injury.","ALL","18 Years",{"count":78,"type":79},42,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.",[85],"Spinal Cord Injuries",[27,87,88],"Neurorecovery","Feasibility","2025-11-24",{"date":91,"type":92},"2025-12-02","ACTUAL",{"date":94,"type":92},"2022-03-14",{"date":96,"type":79},"2026-08-31",{"name":5,"class":6},1]